Abstracts tagged "Eosinophilic Granulomatosus with Polyangiitis (Churg-Strauss)"

Abstract Number: 1605 • ACR Convergence 2024
Characteristics of Relapses in Patients with Eosinophilic Granulomatosis with Polyangiitis
Peter Merkel¹, David Jayne², Ulrich Specks³, Christian Pagnoux⁴, Parameswaran Nair⁵, Nader Khalidi⁵, Arnaud Bourdin⁶, Lena Börjesson Sjö⁷, Sofia Necander⁷, Anat Shavit⁸, Claire Walton⁹ and Michael Wechsler¹⁰, ¹University of Pennsylvania, Philadelphia, PA, ²University of Cambridge, Cambridge, United Kingdom, ³Mayo Clinic, Rochester, MN, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵McMaster University and St Joseph’s Healthcare, Hamilton, ON, Canada, ⁶Department of Respiratory Diseases, University of Montpellier, CHU Montpellier, PhyMedExp, INSERM, CNRS, Montpellier, France, ⁷Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁸BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁹Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁰National Jewish Health, Denver, CO
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by asthma, eosinophilia, and small-to-medium size vessel vasculitis. In the Phase 3, double-blind,…
Abstract Number: 1606 • ACR Convergence 2024
Demographic and Treatment Patterns in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Cohort Analysis of US Claims and Clinical Data
Paul Dolin¹, Anat Shavit¹, Karina A. Keogh², Jennifer Rowell³, Chris Edmonds⁴, James M. Eudicone⁵, Amanda M. Moore⁶, Melissa Wilson⁷, Kinwei A. Chan⁶, Thomas Peer⁸ and Stephanie Y. Chen⁹, ¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ²Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic,, Rochester, MN, ³Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, ⁴Market Access and Pricing, AstraZeneca, Gaithersburg, MD, ⁵Real World Science and Analytics, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ⁶TriNetX, Cambridge, MA, ⁷TriNetX, Durham, NC, ⁸TriNetX, Farmington, NY, ⁹BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by chronic necrotizing vasculitis. Conventional therapy (oral glucocorticoids [OGC] ± immunosuppressants), mepolizumab, and…
Abstract Number: 1607 • ACR Convergence 2024
Low Concentrations of Anti-C5a Complement Receptor Antibodies Are Associated with Relapse in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Sebastian Klapa¹, Sabrina Arnold², Antje Müller², Andreas Koch³, Anja Staehle⁴, Wataru Kähler³, Harry Heidecke⁵, Gabriela Riemekasten² and Peter Lamprecht², ¹University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, ²University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, ³Christian-Albrechts-University Kiel, Institute of Experimental Medicine, Kiel, Germany, ⁴University of Lübeck, Department of Rheumatology and Immunology, Lübeck, Germany, ⁵CellTrend GmbH, Luckenwalde, Germany
Background/Purpose: Complement activation has been shown to play an important role in the pathogenesis of the two major anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) variants,…
Abstract Number: 1608 • ACR Convergence 2024
Interstitial Lung Disease in ANCA-associated Vasculitis: A Retrospective Study of Clinical Characteristics, Radiographic Features, and Outcomes
Janelle Castellino¹, Matas Orentas², Joshua Moran³, Joshlean Fair¹, Yanyu Zhang⁴ and Aleksandra Bukiej⁵, ¹Rush University Medical Center, Chicago, IL, ²RUMC, Chicago, IL, ³Rush University Medical Center - IM Residency, Chicago, IL, ⁴Rush University Medical Center, Chicago, ⁵Rush University Medical Center, River Forest, IL
Background/Purpose: Interstitial lung disease (ILD) is a significant manifestation of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and…
Abstract Number: 1611 • ACR Convergence 2024
Impact of Mepolizumab on Patient-reported Outcomes in Eosinophilic Granulomatosis with Polyangiitis by Using the ANCA-associated Vasculitis Patient-reported Outcomes (AAV-PRO) Questionnaire: A European Multicentre Prospective Study
Paolo Delvino¹, Luca Quartuccio², Joanna Robson³, Federico Alberici⁴, Diego Bagnasco⁵, Alvise Berti⁶, Marco Caminati⁷, Marta Camoni⁸, Maria Cid⁹, Edoardo Conticini¹⁰, Giulia Costanzo¹¹, Claire de Moreuil¹², Stefano Del Giacco¹¹, Georgina Espigol-Frigole¹³, Virginia V Ferretti¹⁴, Franco Franceschini¹⁵, Luca Iorio¹⁶, Anna Kernder¹⁷, Catherine Klersy¹⁴, Alberto Lo Gullo¹⁸, Laura Losappio¹⁹, Elena Manna²⁰, Matteo Maule²¹, Carlomaurizio Montecucco²², Negrini Simone²³, Roberto Padoan²⁴, Francesca Regola²⁵, Luisa Ricciardi²⁶, Jan Schroeder¹⁹, Benjamin Terrier²⁷, Paola Toniati²⁸, Elena Treppo², Maria-Letizia Urban²⁹, Augusto Vaglio³⁰, Giacomo Emmi³¹ and Sara Monti³², and European EGPA Study Group, ¹University of Milano-Bicocca, Milan, Milan, Italy, ²Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy, ³UWE Bristol, Bristol, United Kingdom, ⁴Nephrology Unit, University of Brescia, ASST Spedali Civili, University of Brescia, Brescia, Italy, Brescia, Italy, ⁵Allergy and Respiratory Diseases, Department of Internal Medicine (DIMI), IRCCS Policlinico San Martino, Genoa, Italy, ⁶University of Trento, Rochester, Italy, ⁷Department of Medicine, Asthma, Allergy and Clinical Immunology Section, University of Verona, Verona, Italy, ⁸Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy, ⁹Hospital Clinic Barcelona. University of Barcelona, Barcelona, Spain, ¹⁰University of Siena, Siena, Siena, Italy, ¹¹Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy, ¹²Service de médecine interne, CHU de Brest, Brest, France, ¹³Hospital Clinic de Barcelona, Barcelona, Spain, ¹⁴Biostatistcs & Clinical Trial Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Pavia, Italy, ¹⁵Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ¹⁶Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padova, Italy, Padova, Italy, ¹⁷HHU Dusseldorf, Dusseldorf, Germany, ¹⁸Rheumatology Unit, Papardo Hospital, Messina, Italy, ¹⁹Division of Allergy and Clinical Immunology, ASST GOM Niguarda, Milan, Milan, Italy, ²⁰Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Pavia, Italy, ²¹Asthma Center and Allergy Unit, Verona Integrated University Hospital, Verona, Verona, Italy, ²²IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ²³Department of Internal Medicine (DIMI), University of Genoa, Genoa, Genoa, Italy, ²⁴Department of Medicine DIMED, Division of Rheumatology, University of Padua, Padua, Italy, ²⁵Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili Brescia and University of Brescia, Brescia, Italy, ²⁶Allergy and Immunology Unit, Department of Clinical and Experimental Medicine, G. Martino Teaching Hospital, University of Messina, Messina, Messina, Italy, ²⁷Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ²⁸Spedali civili, 25123, Italy, ²⁹Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ³⁰Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Firenze, Florence, Italy, ³¹University of Trieste, Trieste, Italy, ³²IRCCS Istituto Auxologico Italiano, Milan, Italy
Background/Purpose: Mepolizumab (MEPO) proved its efficacy in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in the randomized controlled MIRRA trial. The ANCA-associated vasculitis patient-reported…
Abstract Number: 0827 • ACR Convergence 2024
Oral Corticosteroid-Sparing Effects of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Results up to 7.4 Years from the Long-Term Access Programme
Paneez Khoury¹, Jared Silver², Gerhard Wolff³, Robert Price⁴, Rejina Verghis⁵, Emmeline Igboekwe² and Michael E Wechsler⁶, ¹National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ²US Medical Affairs-Respiratory, GSK, Durham, ³Clinical Development-Respiratory, GSK, Collegeville, ⁴Biostatistics, GSK, Stevenage, United Kingdom, ⁵Biostatistics, Development Respiratory, GSK, Brentford, United Kingdom, ⁶Department of Medicine, National Jewish Health, Denver, CO
Background/Purpose: EGPA is a severe, rare, relapsing/remitting inflammatory disease, in which chronic or high oral corticosteroid (OCS) doses lead to adverse effects, adding to disease…
Abstract Number: 2000 • ACR Convergence 2024
Induction of Systemic Inflammatory Diseases with Dupilumab Therapy
Jeanne Tisseau des Escotais¹, Camille Taille², Julie Merindol³, Matthieu Groh⁴, Perrine SMETS⁵, Amel Boudjemaa⁶, Alexandra Audemard⁷, Nabil Belfeki⁸, Philippe Bonniaud⁹, Chloe Comarmond¹⁰, Isabelle DELACROIX¹¹, Charlotte Descours¹², Lucile Grange¹³, Paul Legendre¹⁴, Nihal Martis¹⁵, Thomas Moulinet¹⁶, Béatrice Walls¹⁷, Laurent Chouchana¹ and Benjamin Terrier¹⁸, ¹Cochin, Paris, France, ²Bichat Hospital, Paris, France, ³Internal Medicine Department, University Hospital of Nice, Côte d'Azur University, Nice, Provence-Alpes-Côte d'Azur, France., Nice, France, ⁴Foch, Suresnes, France, ⁵Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ⁶CHU créteil, Créteil, France, ⁷Tours, Tours, France, ⁸CH Melun, Melun, France, ⁹Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adulte, Service de Pneumologie et Soins Intensifs Respiratoires, Centre Hospitalo-Universitaire de Dijon-Bourgogne, Dijon, France, ¹⁰Lariboisière University Hospital, Paris, France, ¹¹CHI créteil, Créteil, France, ¹²CH Tours, Tours, France, ¹³CH Saint-Etienne, Saint-Etienne, France, ¹⁴Service Médecine Interne et Polyvalente, Centre Hospitaliers Le Mans, Le Mans, France, ¹⁵CH Nice, Nice, France, ¹⁶CHRU de Nancy, Vandœuvre-lès-Nancy, France, ¹⁷Paris, Paris, France, ¹⁸Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Dupilumab is a monoclonal antibody directed against the alpha subunit of the interleukin (IL)-4 receptor, blocking interleukin (IL)-4 and IL-13 signaling. It is approved…
Abstract Number: 0828 • ACR Convergence 2024
Efficacy of Eosinophil-Targeting Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis in the Phase 3 MANDARA Trial
Peter Merkel¹, David Jayne², Ulrich Specks³, Christian Pagnoux⁴, Benjamin Terrier⁵, Bernhard Hellmich⁶, Sofia Necander⁷, Anat Shavit⁸, Claire Walton⁹ and Michael Wechsler¹⁰, ¹University of Pennsylvania, Philadelphia, PA, ²University of Cambridge, Cambridge, United Kingdom, ³Mayo Clinic, Rochester, MN, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ⁶Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁷Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁸BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁹Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁰National Jewish Health, Denver, CO
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by small- to medium-vessel vasculitis, asthma and eosinophilia. In the head-to-head MANDARA trial…
Abstract Number: 2479 • ACR Convergence 2024
Mepolizumab Treatment Decreased Oral Corticosteroid Use and Improved Clinical Response, Control Status, and Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis: Results up to 24 Months from a Large Network of US Allergy Practices
Michael E Wechsler¹, Anna Kovalszki², Jared Silver³, Brian Stone⁴, Lior Seluk⁵, Lynn Huynh⁶, Wilson da Costa Junior⁶, Mingchen Ye⁶, Jeremiah Hwee⁷, Mei Sheng Duh⁶, William McCann⁴ and Amy G. Edgecomb⁸, ¹Department of Medicine, National Jewish Health, Denver, CO, ²Division of Allergy and Clinical Immunology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ³US Medical Affairs - Respiratory, GSK, Durham, ⁴Allergy Partners, Asheville, NC, ⁵Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, ⁶Analysis Group, Boston, MA, ⁷Value Evidence and Outcomes, GSK, Mississauga, Canada, ⁸US Value, Evidence, & Outcomes, Anti-Infectives and Respiratory, GSK, Philadelphia
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a severe rare systemic inflammatory disease characterized by elevated blood eosinophil counts ≥1000 cells/µL and vasculitis of small-…
Abstract Number: 1254 • ACR Convergence 2024
The Impact of Eosinophilic Granulomatosis with Polyangiitis on the Health-Related Quality of Life of Patients and Their Ability to Work: Evidence from a Real-World Survey in Clinical Practice
Robert Spiera¹, Paul Dolin², Anat Shavit², Jennifer Rowell³, Chris Edmonds⁴, Josefine Persson⁵, Danuta Kielar⁶, Daniel Mascia⁷, James Siddall⁷, Tia Pennant⁷, Fritha Hennessy⁷ and Stephanie Y. Chen⁸, ¹Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ²BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ³Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, ⁴Market Access and Pricing, AstraZeneca, Gaithersburg, MD, ⁵Market Access and Pricing, AstraZeneca, Gothenburg, Sweden, ⁶Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom, ⁷Adelphi Real World, Bollington, United Kingdom, ⁸BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare anti-neutrophil cytoplasmic antibody-associated vasculitis that confers significant disease burden. This real-world study described the impact of…
Abstract Number: 2482 • ACR Convergence 2024
Long-Term Safety of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pooled Results from Two Open-Label Extension Studies
Gerhard Wolff¹, Michael E Wechsler², Jared Silver³, Robert Price⁴, Rejina Verghis⁵, Peter Weller⁶, Peter Merkel⁷, Thomas Corbridge⁸ and Paneez Khoury⁹, ¹Clinical Development-Respiratory, GSK, Collegeville, ²Department of Medicine, National Jewish Health, Denver, CO, ³US Medical Affairs-Respiratory, GSK, Durham, ⁴Biostatistics, GSK, Stevenage, United Kingdom, ⁵Biostatistics, Development Respiratory, GSK, Brentford, United Kingdom, ⁶Beth Israel Deaconess Medical Center, Department of Medicine, Division of Allergy and Inflammation, Harvard Medical School, Boston, MA, ⁷Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ⁸US Value Evidence and Outcomes, GSK, Durham, NC, ⁹National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: The 52-week Phase III MIRRA trial demonstrated the safety and efficacy of anti-IL-5 mepolizumab in patients with EGPA. However, longer-term safety data are limited.…
Abstract Number: 1592 • ACR Convergence 2024
Overlapping Forms of Eosinophilic Granulomatosis with Polyangiitis and Granulomatosis with Polyangiitis: Presentation, Management and Outcomes
Federica Pallotti¹, Camille Mettler², Roberto Padoan³, Francesca Regola⁴, Franco Franceschini⁵, Sergey Moiseev⁶, Pavel Novikov⁷, Mario Andrea Piga⁸, Gianluca Moroncini⁹, Silke Brix¹⁰, Abdul Hadi Kafagi¹¹, Samuel Deshayes¹², Achille Aouba¹², Julien Campagne¹³, Paolo Delvino¹⁴, Jan Willem Cohen Tervaert¹⁵, Luisa Brussino¹⁶, Martin Michaud¹⁷, Nils Venhoff¹⁸, Federico Alberici¹⁹, Claudia Iannone²⁰, Sophie Rosenstingl²¹, Marin Moutel²², Jean-Marc Galempoix²³, Vincent Cottin²⁴, Clara Jaccard²⁵, Diane Riehl²⁶, Paul Legendre²⁷, Anne-Claire Billet²⁸, Paola Parronchi²⁹, Luca Quartuccio³⁰, Vítor Silvestre Teixeira³¹, Allyson Egan³², David Jayne³², Enrico Tombetti³³, Marco Caminati³⁴, Christian Pagnoux³⁵, Alexis Régent³⁶, Marc Ruivard³⁷, Loïc Guillevin³⁸, Xavier Puéchal³⁶ and Benjamin Terrier³⁹, and the French Vasculities Study Group and European EGPA Study Group, ¹Internal Medicine, Centre Hospitalier Universitaire de Caen, Caen, France, ²Département de Médecine Interne, Centre de Référence National pour les maladies auto-immunes systémiques rares, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France, ³Department of Medicine DIMED, Division of Rheumatology, University of Padua, Padua, Italy, ⁴Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili Brescia and University of Brescia, Brescia, Italy, ⁵Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ⁶Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia, ⁷Sechenov First Moscow State Medical University, Moscow, Russia, ⁸Postgraduate School of Allergy and Clinical Immunology, Università Politecnica delle Marche, Ancona, Italy, ⁹Department of Clinical and Molecular Sciences, Marche Polytechnic University & Department of Internal Medicine, Marche University Hospital, Ancona, Italy, ¹⁰Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, The University of Manchester, Manchester, United Kingdom, ¹¹Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester, United Kingdom, ¹²Service d'immunologie clinique-médecine interne, CHU de Caen Normandie, Caen, France, ¹³Hôpital Robert Schuman - Competence center for autoimmune diseases, Internal Medicine, Metz, France, ¹⁴University of Milano-Bicocca, Milan, Milan, Italy, ¹⁵University of Alberta, Edmonton, Canada, ¹⁶SSDDU Immunologia Clinica ed Allergologia, AO Mauriziano, Turin, Italy, ¹⁷Department of Internal Medicine, Clinique Saint-Exupery, Toulouse, France., Toulouse, France, ¹⁸Medical Center - University of Freiburg, Internal Medicine, Department of Rheumatology and Clinical Immunology, Freiburg, Germany, ¹⁹Nephrology Unit, ASST Spedali Civili di Brescia, Brescia, Italy, ²⁰Department of Rheumatology, University of Milan, and Rheumatology Department, ASST Pini-CTO, Milan, Italy, ²¹Service Médecine Interne, Centre hospitalier intercommunal Compiègne Noyon, Compiègne Noyon, France, ²²Department of Internal Medicine, Infectious Diseases, and Clinical Immunology, Reims University Hospital, Reims, France, ²³J.M. Galempoix, MD, Department of Internal Medicine, Nord Ardennes Hospital, Charleville-Mézières, France, ²⁴Hôpital Louis Pradel, Centre de Référence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France, Lyon, France, ²⁵Gaston Bourret Hospital, Nouméa, New Caledonia, ²⁶Centre hospitalier intercommunal Toulon- La Seyne Sur Mer, Toulon, France, ²⁷Service Médecine Interne et Polyvalente, Centre Hospitaliers Le Mans, Le Mans, France, ²⁸Department of Internal Medicine, Édouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France, ²⁹University of Florence, Florence, Florence, Italy, ³⁰Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, ³¹Department of Rheumatology, Faro Hospital, Algarve, Portugal, ³²University of Cambridge, Cambridge, United Kingdom, ³³Internal Medicine and Rheumatology, Department of Biomedical and Clinical Sciences, Sacco and Fatebenefratelli Hospitals, Milan, Italy, Milan, Italy, ³⁴Department of Medicine, Asthma, Allergy and Clinical Immunology Section, University of Verona, Verona, Italy, ³⁵Mount Sinai Hospital, Toronto, ON, Canada, ³⁶National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ³⁷Internal Medicine Department, Estaing University Hospital, CHU Clermont-Ferrand, Clermonnt-Ferrand, Italy, ³⁸National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ³⁹Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: ANCA-associated vasculitis (AAV) include granulomatosis with polyangiitis (GPA), microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis (EGPA). Although these entities are often easily distinguished in…
Abstract Number: 2491 • ACR Convergence 2024
Treatment Outcomes of Eosinophilic Granulomatosis with Polyangiitis (EGPA):A Retrospective Analysis of US Health Insurance Claims Data
Paul Dolin¹, Anat Shavit¹, Karina A. Keogh², Jennifer Rowell³, Chris Edmonds⁴, Danuta Kielar⁵, Juliana Meyers⁶, Elizabeth Esterberg⁶, Tram Nham⁶ and Stephanie Y. Chen⁷, ¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ²Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic,, Rochester, MN, ³Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, ⁴Market Access and Pricing, AstraZeneca, Gaithersburg, MD, ⁵Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom, ⁶RTI Health Solutions, Research Triangle Park, NC, ⁷BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis disorder characterized by asthma, eosinophilia and the presence of eosinophilic inflammation. Patients with EGPA are…
Abstract Number: 1593 • ACR Convergence 2024
Efficacy of Increasing the Dose of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis
Federica Pallotti¹, Philippe Bonniaud², Perrine SMETS³, stephanie Habib⁴, Amandine Perier⁵, Alban Deroux⁶, Julie Mankikian⁷, Antoine Neel⁸, Clémentine Rousselin⁹, Raphaele Seror¹⁰, Camille Taille¹¹, Etienne Crickx¹², Candice La Croix¹³, Philippe Blanche¹⁴, Loïc Guillevin¹⁵, Xavier Puéchal¹⁶ and Benjamin Terrier¹⁷, and French Vasculitis Study Group, ¹Internal Medicine, Centre Hospitalier Universitaire de Caen, Caen, France, ²Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adulte, Service de Pneumologie et Soins Intensifs Respiratoires, Centre Hospitalo-Universitaire de Dijon-Bourgogne, Dijon, France, ³Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ⁴Service de Pneumologie, Hôpital Cochin, APHP Centre et Université Paris Cité, Paris, France, ⁵CH de Niort, Niort, France, ⁶Clinique Universitaire de Médecine Interne, Department of Internal Medicine, Grenoble University Hospital, Grenoble, France, ⁷CHRU Tours, Service de Pneumologie et d'Explorations Fonctionnelles Respiratoires, Tours, France, ⁸Department of Internal Medicine, CHU Nantes, Nantes, France, ⁹Service de médecine interne et néphrologie, centre hospitalier de Valenciennes, Valenciennes, France, ¹⁰Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ¹¹Bichat Hospital, Paris, France, ¹²Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l'adulte, Hôpital Henri Mondor, APHP, Paris, France, ¹³Department of Otolaryngology, Hôpital Cochin, APHP, Paris, France, ¹⁴Department of Internal Medicine, National Referrence Center for Systemic and Autoimmune Diseases, Hôpital Cochin, APHP, Paris, France, ¹⁵National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ¹⁶National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ¹⁷Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) patients frequently develop glucocorticoid (GC)-dependent asthma and/or ENT manifestations, leading to long-term GC requirement and side effects. Mepolizumab, an…
Abstract Number: 2691 • ACR Convergence 2024
Transcriptomic Changes in CD4+ T Lymphocytes in Eosinophilic Granulomatosis with Polyangiitis
Roberto Ríos-Garcés¹, Núria Farran¹, Salvador Naranjo-Suarez², Roser Alba-Rovira¹, Sergio Prieto-González³, Itziar Tavera-Bahillo¹, Roser Solans-Laqué⁴, Ebymar Arismendi⁵, Marc Corbera-Bellalta¹, Javi Marco-Hernández¹, Farah Kamberovic¹, Nina Visocnik¹, Maria Cid⁶ and Georgina Espígol-Frigolé¹, ¹Vasculitis Research Group, Autoimmune Diseases Department, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain, ²Angiogenesis in Liver Disease Research Group, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain, ³Vasculitis Research Group, Autoimmune Diseases Department, IDIBAPS, Hospital Clinic, University of Barcelona, bar, Spain, ⁴Internal Medicine Service, Vall d'Hebron Hospital University and Campus, Barcelona, Spain, ⁵Pneumology Department, Hospital Clinic, IDIBAPS, University of Barcelona, CIBERES, Barcelona, Spain, ⁶Hospital Clinic Barcelona. University of Barcelona, Barcelona, Spain
Background/Purpose: Eosinophilic Granulomatosis with polyangiitis (EGPA) is a rare systemic autoimmune disorder, included within the ANCA-associated vasculitis. It is characterized by a diverse clinical profile,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].